Literature DB >> 35144657

Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial.

Christopher Kai Shun Leung1,2,3, Seraph Tianmin Ren4, Poemen Pui Man Chan5,4, Kelvin Ho Nam Wan5,4, Aziz Ka Wai Kam4, Gilda Wing Ki Lai6, Vivian Sheung Man Chiu6, Match Wai Lun Ko7, Cedric Ka Fai Yiu8, Marco Chak Yan Yu9.   

Abstract

Entities:  

Year:  2022        PMID: 35144657      PMCID: PMC8832638          DOI: 10.1186/s13063-022-06079-1

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


× No keyword cloud information.
Correction to: Leung 23:45 (2022) https://doi.org/10.1186/s13063-021-05968-1 Following the publication of the original article [1], we were notified that the received date of the paper was 26 November 2020, and not 8 March 2021. The original article has been corrected.
  1 in total

1.  Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial.

Authors:  Christopher Kai Shun Leung; Seraph Tianmin Ren; Poemen Pui Man Chan; Kelvin Ho Nam Wan; Aziz Ka Wai Kam; Gilda Wing Ki Lai; Vivian Sheung Man Chiu; Match Wai Lun Ko; Cedric Ka Fai Yiu; Marco Chak Yan Yu
Journal:  Trials       Date:  2022-01-17       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.